We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility
Read MoreHide Full Article
Key Takeaways
GEHC's Q2 organic orders rose 11.1%, with book-to-bill at 1.15X and backlog reaching a record $23.9B.
GE HealthCare entered Q3 with nearly 85% of equipment revenue secured and reaffirmed 3%-4% growth.
GEHC must improve PCS execution and offset about $250M of expected 2026 inflation to support margins.
GE HealthCare Technologies Inc. (GEHC - Free Report) delivered a notable demand signal in the second quarter, with organic orders rising 11.1% year over year. Book-to-bill reached 1.15X and backlog climbed to a record $23.9 billion.
The key question is how much of that demand can convert into profitable revenues. Backlog visibility is improving, but execution in Patient Care Solutions and inflation remain important constraints.
GEHC’s Order Surge Was Broad Based
Management said second-quarter order growth was broad based across every segment and included no material one-time items. The two-year order-growth stack exceeded 7%, supporting the view that demand strength extended beyond one quarter.
Orders also rose across Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions. That breadth matters because it reduces dependence on a single product category as GEHC moves through a multi-year innovation cycle.
GE HealthCare Enters Q3 With Revenue Secured
Nearly 85% of equipment revenue entering the third quarter was already secured. GE HealthCare expects third-quarter organic revenue growth of 3% to 4%, providing a clearer bridge from backlog to near-term sales conversion.
The company also reaffirmed full-year organic revenue growth guidance of 3% to 4%. Execution remains the deciding factor, particularly as longer-cycle equipment orders require manufacturing, installation and customer-site readiness before they become revenues.
Image Source: Zacks Investment Research
GEHC’s Backlog Could Extend Into 2027
The $23.9 billion backlog was up $2.6 billion year over year. Management said some of the strongest order growth came from longer-cycle radiology products, which are expected to contribute more meaningfully to revenues in 2027.
That timing gives GEHC visibility beyond the current year, but it also shifts attention toward conversion quality. Investors will need to watch whether backlog growth translates into sustainable revenue gains rather than simply extending delivery schedules.
GE HealthCare’s New Products Can Lift the Mix
Photonova Spectra, True Definition DL and Vivid Pioneer are part of GE HealthCare’s imaging and ultrasound innovation cycle. Management said Vivid Pioneer is generating a higher gross margin than the prior platform, helped by lower manufacturing costs and AI-enabled features that support pricing.
Koninklijke Philips N.V. (PHG - Free Report) is also refreshing its imaging portfolio, including AI-powered magnetic resonance imaging and image-guided therapy technologies. Medtronic plc (MDT - Free Report) is expanding real-time AI capabilities in surgery, illustrating how product innovation and workflow productivity remain central competitive themes across medical technology.
GEHC Must Turn Orders Into Profitable Revenue
Patient Care Solutions shows why strong demand alone is insufficient. Second-quarter PCS revenues declined 13.3% year over year and segment EBIT was negative, with operational and fulfillment challenges limiting backlog conversion.
Inflation adds another hurdle. GE HealthCare continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components. Pricing, productivity and improved shipment velocity therefore remain important to converting backlog into margin expansion.
GEHC’s Near-Term Signal Supports the Backlog Story
GEHC’s record backlog and broad order growth improve revenue visibility, but the investment theme still depends on execution. The company must convert demand while stabilizing PCS and offsetting input-cost pressure.
GEHC currently carries a Zacks Rank #2 (Buy). Its Value Score of B is favorable for value-oriented investors, while the Growth Score of D and Momentum Score of F are weaker. The VGM Score of C reflects a mixed blend across value, growth and momentum, reinforcing the need to balance the positive near-term Rank with execution risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) delivered a notable demand signal in the second quarter, with organic orders rising 11.1% year over year. Book-to-bill reached 1.15X and backlog climbed to a record $23.9 billion.
The key question is how much of that demand can convert into profitable revenues. Backlog visibility is improving, but execution in Patient Care Solutions and inflation remain important constraints.
GEHC’s Order Surge Was Broad Based
Management said second-quarter order growth was broad based across every segment and included no material one-time items. The two-year order-growth stack exceeded 7%, supporting the view that demand strength extended beyond one quarter.
Orders also rose across Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions. That breadth matters because it reduces dependence on a single product category as GEHC moves through a multi-year innovation cycle.
GE HealthCare Enters Q3 With Revenue Secured
Nearly 85% of equipment revenue entering the third quarter was already secured. GE HealthCare expects third-quarter organic revenue growth of 3% to 4%, providing a clearer bridge from backlog to near-term sales conversion.
The company also reaffirmed full-year organic revenue growth guidance of 3% to 4%. Execution remains the deciding factor, particularly as longer-cycle equipment orders require manufacturing, installation and customer-site readiness before they become revenues.
Image Source: Zacks Investment Research
GEHC’s Backlog Could Extend Into 2027
The $23.9 billion backlog was up $2.6 billion year over year. Management said some of the strongest order growth came from longer-cycle radiology products, which are expected to contribute more meaningfully to revenues in 2027.
That timing gives GEHC visibility beyond the current year, but it also shifts attention toward conversion quality. Investors will need to watch whether backlog growth translates into sustainable revenue gains rather than simply extending delivery schedules.
GE HealthCare’s New Products Can Lift the Mix
Photonova Spectra, True Definition DL and Vivid Pioneer are part of GE HealthCare’s imaging and ultrasound innovation cycle. Management said Vivid Pioneer is generating a higher gross margin than the prior platform, helped by lower manufacturing costs and AI-enabled features that support pricing.
Koninklijke Philips N.V. (PHG - Free Report) is also refreshing its imaging portfolio, including AI-powered magnetic resonance imaging and image-guided therapy technologies. Medtronic plc (MDT - Free Report) is expanding real-time AI capabilities in surgery, illustrating how product innovation and workflow productivity remain central competitive themes across medical technology.
GEHC Must Turn Orders Into Profitable Revenue
Patient Care Solutions shows why strong demand alone is insufficient. Second-quarter PCS revenues declined 13.3% year over year and segment EBIT was negative, with operational and fulfillment challenges limiting backlog conversion.
Inflation adds another hurdle. GE HealthCare continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components. Pricing, productivity and improved shipment velocity therefore remain important to converting backlog into margin expansion.
GEHC’s Near-Term Signal Supports the Backlog Story
GEHC’s record backlog and broad order growth improve revenue visibility, but the investment theme still depends on execution. The company must convert demand while stabilizing PCS and offsetting input-cost pressure.
GEHC currently carries a Zacks Rank #2 (Buy). Its Value Score of B is favorable for value-oriented investors, while the Growth Score of D and Momentum Score of F are weaker. The VGM Score of C reflects a mixed blend across value, growth and momentum, reinforcing the need to balance the positive near-term Rank with execution risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.